About Us
Research Projects
Research Staff
Career Opportunities
Contact Us
Employee Advisories
Research Projects

Principal Investigator:  Scott Evans, Ph.D.

Antibacterial resistance is one of the greatest threats to human health worldwide. The Antibacterial Resistance Leadership Group (ARLG) is a national resource funded by National Institute of Allergy and Infectious Diseases (NIAID) to design, prioritize, conduct, and manage an integrated clinical research program to address antibacterial resistance scientific priorities. The ARLG has four scientific subcommittees: (1) Gram Positive, (2) Gram Negative, (3) Diagnostic and Devices, and (4) Stewardship and Infection Control, e.g., surveillance. Three special emphasis panels, (1) Pharmacology, (2) Pediatrics, and (3) Special Populations assist the scientific subcommittees. The ARLG also has an active Mentoring Program for early-career researchers.

Located at BSC, the Statistical and Data Analysis Center (SDAC) of the Statistical and Data Management Center (SDMC) provides the ARLG with statistical expertise to advance the ARLG research agenda. The ARLG SDAC is active at all stages of a study, including design; data collection and monitoring; data analyses and archival; and publication of study results. The SDAC enhances the scientific integrity of ARLG studies through the development and implementation of innovative and practical statistical methodologies and by educating research colleagues regarding the application of the fundamentals of clinical trials, observational studies, and diagnostic studies.

Professor Scott Evans, Director of the BSC, is the Director of the SDMC for the ARLG. Other BSC members of the ARLG team include Michelle Earley, Yunyun Jiang, Lauren Komarow, and Thuy Tran-Fisher.

Recent ARLG Papers

Evans SR, Powers J. Evaluating Anti-Infective Drugs in the Resistant Pathogen Setting: Can we Use External Controls? Statistical communications in infectious diseases. Published Online: 2017-03-14 | DOI: https://doi.org/10.1515/scid-2016-0003

Chambers HF, Cross HR, Evans SR, Kreiswirth BN, Fowler VG Jr; Antibacterial Resistance Leadership Group (ARLG). The Antibacterial Resistance Leadership Group: Progress Report and Work in Progress. Clin Infect Dis. 2017 Mar 15;64(suppl_1):S3-S7. doi: 10.1093/cid/ciw824. PubMed PMID: 28350896.

Huvane J, Komarow L, Hill C, Tran TT, Pereira C, Rosenkranz SL, Finnemeyer M, Earley M, Jiang HJ, Wang R, Lok J, Evans SR; Statistical and Data Management Center of the Antibacterial Resistance Leadership Group (ARLG). Fundamentals and Catalytic Innovation: The Statistical and Data Management Center of the Antibacterial Resistance Leadership Group. Clin Infect Dis. 2017 Mar 15;64(suppl_1):S18-S23. doi: 10.1093/cid/ciw827. PubMed PMID: 28350899.

Evans SR, Follmann D. Using Outcomes to Analyze Patients Rather than Patients to Analyze Outcomes: A Step toward Pragmatism in Benefit:risk Evaluation. Statistics in Biopharmaceutical Research. 2016 December;8(4):386-393. doi: 10.1080/19466315.2016.1207561.

Evans SR, Pennello G, Pantoja-Galicia N, Jiang H, Hujer AM, Hujer KM, Manca C, Hill C, Jacobs MR, Chen L, Patel R, Kreiswirth BN, Bonomo RA; Antibacterial Resistance Leadership Group. Benefit-risk Evaluation for Diagnostics: A Framework (BED-FRAME). Clin Infect Dis. 2016 Sep 15;63(6):812-7. doi: 10.1093/cid/ciw329. PubMed PMID: 27193750; PubMed Central PMCID: PMC4996133.

Evans SR, Hujer AM, Jiang H, Hill CB, Hujer KM, Mediavilla JR, Manca C, Tran TT, Domitrovic TN, Higgins PG, Seifert H, Kreiswirth BN, Patel R, Jacobs MR, Chen L, Sampath R, Hall T, Marzan C, Fowler VG Jr, Chambers HF, Bonomo RA. Informing Antibiotic Treatment Decisions: Evaluating Rapid Molecular Diagnostics To Identify Susceptibility and Resistance to Carbapenems against Acinetobacter spp. in PRIMERS III. J Clin Microbiol. 2016 Dec 28;55(1):134-144. doi: 10.1128/JCM.01524-16. PubMed PMID: 27795336; PubMed Central PMCID: PMC5228224.

Evans SR, Harris AD. Methods and issues in studies of CRE. Virulence. 2017 May 19;8(4):453-459. doi: 10.1080/21505594.2016.1213473. Epub 2016 Jul 28. PubMed PMID: 27470534.

Patel R, Tsalik EL, Petzold E, Fowler VG Jr, Klausner JD, Evans S; Antibacterial Resistance Leadership Group (ARLG). MASTERMIND: Bringing Microbial Diagnostics to the Clinic. Clin Infect Dis. 2017 Feb 1;64(3):355-360. doi: 10.1093/cid/ciw788. PubMed PMID: 27927867.

Evans SR, Follmann D. Comment: Fundamentals and Innovation in Antibiotic Trials. Stat Biopharm Res. 2015;7(4):331-336. PubMed PMID: 27087893; PubMed Central PMCID: PMC4831648.

Evans SR, Rubin D, Follmann D, Pennello G, Huskins WC, Powers JH, Schoenfeld D, Chuang-Stein C, Cosgrove SE, Fowler VG Jr, Lautenbach E, Chambers HF. Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR). Clin Infect Dis. 2015 Sep 1;61(5):800-6. doi: 10.1093/cid/civ495. PubMed PMID: 26113652; PubMed Central PMCID: PMC4542892.

Evans SR, Hujer AM, Jiang H, Hujer KM, Hall T, Marzan C, Jacobs MR, Sampath R, Ecker DJ, Manca C, Chavda K, Zhang P, Fernandez H, Chen L, Mediavilla JR, Hill CB, Perez F, Caliendo AM, Fowler VG Jr, Chambers HF, Kreiswirth BN, Bonomo RA; Antibacterial Resistance Leadership Group. Rapid Molecular Diagnostics, Antibiotic Treatment Decisions, and Developing Approaches to Inform Empiric Therapy: PRIMERS I and II. Clin Infect Dis. 2016 Jan 15;62(2):181-9. doi: 10.1093/cid/civ837. PubMed PMID: 26409063; PubMed Central PMCID: PMC4690483.

Chambers HF, Bartlett JG, Bonomo RA, Chiou C, Cosgrove SE, Cross HR, Daum RS, Downing M, Evans SR, Knisely J, Kreiswirth BN, Lautenbach E, Mickley BS, Patel R, Pettigrew MM, Rodvold KA, Spellberg B, Fowler VG Jr. Antibacterial resistance leadership group: open for business. Clin Infect Dis. 2014 Jun;58(11):1571-6. doi: 10.1093/cid/ciu132. Review. PubMed PMID: 24610430; PubMed Central PMCID: PMC4017892

Huskins C, Fowler V, Evans SR. Adaptive Designs for Clinical Trials: Application to Healthcare Epidemiology Research. CID. 2018.

Van Duin D, Lok J, Earley M, Cober E, Richter S, Perez F, Salata R, Kalayjian R, Watkins R, Doi Y, Kaye K, Fowler V, Paterson D, Bonomo R, Evans SR. Colistin vs. Ceftazidime-avibactam in the Treatment of Infections due to Carbapenem-Resistant Enterobacteriaceae, CID, 2017.)